Literature DB >> 15043311

Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome.

Jinru Shia1, Jose G Guillem, Harvey G Moore, Satish K Tickoo, Jing Qin, Leyo Ruo, Arief Suriawinata, Philip B Paty, Bruce D Minsky, Martin R Weiser, Larissa K Temple, W Douglas Wong, David S Klimstra.   

Abstract

Preoperative radiation (RT) and chemotherapy improve outcome in patients with locally advanced rectal adenocarcinoma and, therefore, have been used increasingly in patient management. The histopathologic alterations in postirradiated rectal adenocarcinoma and their prognostic significance have not been fully characterized. In this study, detailed analyses of morphologic alterations of stromal and tumor cells were performed in a series of 66 posttreatment rectal carcinomas, and the pathologic findings were correlated with long-term outcome. All tumors were locally advanced, with a bulky and/or tethered tumor or endorectal ultrasound or magnetic resonance imaging evidence of T3-4 and / or N1 disease. All patients were treated at one institution with preoperative RT to the pelvis (at least 4500 cGy) with or without concurrent 5-fluorouracil (5-FU)-based chemotherapy 4 to 7 weeks prior to surgical resection. Pathologic assessment showed some treatment response in all patients. Nine patients (13.4%) had complete response, and 8 (11.9%) had near-complete response (> 95% of the tumor replaced by fibroinflammatory tissue). Salient morphologic features included marked fibrosis with or without prominent inflammatory cells replacing neoplastic glands; lack of active tumor necrosis; increased mucin production and mucin pools; marked cytoplasmic eosinophilia, often in combination with marked nuclear atypia but without active mitoses in tumor cells showing treatment effect; endocrine tumor phenotype; and retention of mucosal adenoma in the presence of tumor regression within the bowel wall. With a median follow-up of 69 months, the estimated 5-year recurrence-free survival (RFS) for the entire group was 79%. By univariate analysis, the residual tumor stage (P < 0.05) and reduction of pretreatment T stage (P = 0.002) significantly correlated with RFS, as did pN stage (P = 0.002) and lymphovascular invasion (P = 0.008). The extent of treatment response did not correlate with RFS (P = 0.4). However, patients with a treatment response > or = 95% seemed to fare better than those with a treatment response < 95% (marginally significant difference in RFS, P = 0.057). Univariate and multivariate analyses identified the following morphologic patterns that were significantly associated with a reduced RFS independent of other risk factors: a fibrotic-type stromal response with minimal inflammatory infiltrates (P = 0.001) and absence of surface ulceration (P = 0.026). Our study represents the first detailed morphologic assessment of rectal carcinomas that have been subjected to long course preoperative RT and chemotherapy. Our results demonstrate distinct morphologic features in treated rectal carcinomas that are prognostically relevant.

Entities:  

Mesh:

Year:  2004        PMID: 15043311     DOI: 10.1097/00000478-200402000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  61 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  [Pathological staging and response evaluation of rectal carcinoma].

Authors:  C Wittekind; B Oberschmid
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

3.  Signet ring cell histology and non-circumferential tumors predict pathological complete response following neoadjuvant chemoradiation in rectal cancers.

Authors:  Sunil Bhanu Jayanand; Ramakrishnan Ayloor Seshadri; Ritesh Tapkire
Journal:  Int J Colorectal Dis       Date:  2010-11-03       Impact factor: 2.571

4.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

5.  Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.

Authors:  Andrea Ambrosini-Spaltro; Fabrizio Salvi; Christine M Betts; Giovanni P Frezza; Antonio Piemontese; Pietro Del Prete; Cristina Baldoni; Maria P Foschini; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

Review 6.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis.

Authors:  Purva Gopal; Pengcheng Lu; Gregory D Ayers; Alan J Herline; Mary K Washington
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

8.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?

Authors:  Marc J Gollub; Ivana Blazic; David D B Bates; Naomi Campbell; Andrea Knezevic; Mithat Gonen; Patricio Lynn; Martin R Weiser; Julio Garcia-Aguilar; Andreas M Hötker; Andrea Cercek; Leonard Saltz
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

10.  Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Authors:  Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.